1. Introduction {#sec1-viruses-11-00907}
===============

Vitamin A and D metabolites function as nuclear hormones and have profound influences on innate and adaptive immune activities \[[@B1-viruses-11-00907],[@B2-viruses-11-00907],[@B3-viruses-11-00907],[@B4-viruses-11-00907],[@B5-viruses-11-00907],[@B6-viruses-11-00907]\]. These micronutrients have each been shown to correlate positively with immune responses in a portion of small animal and clinical studies \[[@B1-viruses-11-00907],[@B2-viruses-11-00907],[@B3-viruses-11-00907],[@B7-viruses-11-00907],[@B8-viruses-11-00907],[@B9-viruses-11-00907],[@B10-viruses-11-00907],[@B11-viruses-11-00907],[@B12-viruses-11-00907],[@B13-viruses-11-00907]\]. Vitamin A, for example, was described by Rahman et al. to improve immune responses toward a diptheria vaccine \[[@B14-viruses-11-00907]\]. Chadha et al. showed that vitamin D correlated positively with immune responses toward influenza virus in a set of cancer patients \[[@B15-viruses-11-00907]\] and others reported that vitamin D could control a variety of infectious pathogens including influenza viruses in humans \[[@B9-viruses-11-00907],[@B16-viruses-11-00907],[@B17-viruses-11-00907],[@B18-viruses-11-00907]\]. Vitamins A and D function in part by binding nuclear hormone receptors. Receptors include the retinoic acid receptor \[RAR\], the peroxisome proliferator-activated receptor β/δ \[PPAR β/δ\], and the vitamin D receptor \[VDR\], each complexed with retinoid X receptor (RXR) as a heterodimer \[[@B19-viruses-11-00907],[@B20-viruses-11-00907]\]. Receptors regulate gene expression by binding nuclear hormone response elements (NHRE) in mammalian DNA \[[@B8-viruses-11-00907],[@B21-viruses-11-00907],[@B22-viruses-11-00907],[@B23-viruses-11-00907],[@B24-viruses-11-00907],[@B25-viruses-11-00907],[@B26-viruses-11-00907],[@B27-viruses-11-00907]\]. Recently, we discovered NHRE within key promoter, enhancer, and switch sites in immunoglobulin gene loci. We found that nuclear hormone receptors could bind these sites, indicating a direct influence of nuclear hormones on antibody expression \[[@B28-viruses-11-00907],[@B29-viruses-11-00907],[@B30-viruses-11-00907],[@B31-viruses-11-00907]\].

Despite the positive influences described above, clinical studies have yielded disparate results \[[@B2-viruses-11-00907],[@B3-viruses-11-00907],[@B4-viruses-11-00907],[@B6-viruses-11-00907],[@B7-viruses-11-00907],[@B8-viruses-11-00907],[@B14-viruses-11-00907],[@B32-viruses-11-00907],[@B33-viruses-11-00907],[@B34-viruses-11-00907],[@B35-viruses-11-00907],[@B36-viruses-11-00907],[@B37-viruses-11-00907],[@B38-viruses-11-00907],[@B39-viruses-11-00907],[@B40-viruses-11-00907],[@B41-viruses-11-00907],[@B42-viruses-11-00907],[@B43-viruses-11-00907],[@B44-viruses-11-00907],[@B45-viruses-11-00907],[@B46-viruses-11-00907],[@B47-viruses-11-00907],[@B48-viruses-11-00907]\]. When Hanekom et al. tested vitamin A therapy in HIV-infected individuals, they identified no improvements in responses toward influenza virus vaccines \[[@B43-viruses-11-00907]\] and when Lee et al. tested correlations between vitamin D levels and antibody titers after influenza virus vaccinations, significant correlations were not found \[[@B49-viruses-11-00907]\]. An influenza virus vaccine study by Sundaram et al. revealed no consistent association between vitamin D levels and the vaccine-induced antibody response in older adults, although there was a greater frequency of post-vaccination 'sero-protection' against H1N1 among vitamin D deficient individuals in the first year of the study \[[@B50-viruses-11-00907]\].

A lack of clarity as to when and how vitamins influence immune responses toward vaccines is concerning because vitamin A and D deficiencies and insufficiencies are prevalent worldwide, affecting both developed and developing countries \[[@B11-viruses-11-00907]\]. Low vitamin levels render individuals vulnerable to infectious diseases \[[@B9-viruses-11-00907],[@B13-viruses-11-00907]\]. Although vitamin supplementation programs are common in developing countries where deficiencies are a known public health concern, they cannot be implemented worldwide without a comprehensive understanding of benefits and risks.

Surprisingly, although there is considerable interest in the independent effects of vitamins A and D on the immune response, the two vitamins are rarely examined together. This is despite the knowledge that vitamins A and D influence numerous cell functions, are closely related, and can be cross-regulated \[[@B8-viruses-11-00907],[@B20-viruses-11-00907],[@B24-viruses-11-00907],[@B26-viruses-11-00907],[@B27-viruses-11-00907],[@B51-viruses-11-00907],[@B52-viruses-11-00907],[@B53-viruses-11-00907],[@B54-viruses-11-00907],[@B55-viruses-11-00907],[@B56-viruses-11-00907],[@B57-viruses-11-00907],[@B58-viruses-11-00907]\]. Unfortunately, when clinical studies are designed to evaluate the influences of vitamin supplements on the immune response, the baseline vitamin A and/or D levels of study participants are often unknown, and the potential consequences of vitamin cross-regulation are rarely considered.

To address knowledge gaps, we designed a pediatric randomized controlled study of influenza virus vaccination that measured baseline vitamin A (using retinol-binding protein \[RBP\] as a surrogate \[[@B59-viruses-11-00907]\]) and 25(OH)D levels among healthy children. Participants were stratified into two groups based on high and low baseline RBP levels and randomized to receive a vitamin A and D supplement (A&D) or a placebo control immediately prior to influenza virus vaccination. The hemagglutination inhibition (HAI) assay, a standard in the field for the assessment of influenza virus vaccines, was used to measure immune responses \[[@B60-viruses-11-00907]\]. We discovered that baseline vitamin levels were critical parameters that determined not only antibody responses toward the influenza virus vaccine but the influence of vitamin supplementation on the immune response.

2. Materials and Methods {#sec2-viruses-11-00907}
========================

2.1. Clinical Protocol {#sec2dot1-viruses-11-00907}
----------------------

### 2.1.1. Enrollment {#sec2dot1dot1-viruses-11-00907}

A randomized, placebo-controlled clinical study was conducted at St. Jude Children's Research Hospital (St. Jude) in Memphis, TN to examine the influences of baseline vitamin levels and vitamin supplementation on immune responses to the influenza virus vaccine (<https://clinicaltrials.gov/ct2/show/NCT02649192>). The study was conducted in accordance with the Declaration of Helsinki, and the protocol (FluVIT, Pro00006109, 5 December 2015) was approved by the Institutional Review Board of St. Jude. Healthy children between 2 to 8 (inclusive) years of age were enrolled over three influenza virus seasons including season 2015--2016 (*n* = 9), season 2016--2017 (*n* = 44), and season 2017--2018 (*n* = 26). Informed consent was given by parents or guardians and assent was given by minors when age-appropriate. Comprehensive histories of previous vaccinations and influenza virus exposures were not available. Participants were excluded from study entry if they had any chronic illness, developmental delay, or neurological disorder. They were also excluded if they were known to have received an influenza vaccine for the current season or were routinely taking a daily vitamin supplement.

### 2.1.2. Randomization and Masking {#sec2dot1dot2-viruses-11-00907}

During the screening visit, sera were collected for measurements of baseline serum RBP (usually present in blood at a 1:1 molar ratio with retinol \[[@B59-viruses-11-00907]\]) for stratification of participants into "high" and "low" groups. Stratification to the "high" (vitamin A sufficient) group was based on a measurement of ≥ 22,000 ng/mL RBP (approximating ≥ 1.05 µM retinol) \[[@B59-viruses-11-00907],[@B61-viruses-11-00907],[@B62-viruses-11-00907],[@B63-viruses-11-00907]\]. Each group was then randomized to receive A&D as an oral gummy vitamin supplement (20,000 IU and 2000 IU per gummy for vitamins A and D, respectively) or a matched gummy that lacked vitamins (placebo). Stratification was performed to prevent an imbalance between placebo and A&D study groups. Gummies were formulated by Regel PharmaLab (Memphis, TN, USA). The components were vitamin A palmitate liquid (\#30-3124, PCCA USA, Houston, TX, USA), vitamin D3 liquid (\#30-1033, PCCA USA), gelatin base (\#30-1520, 830 mg/dose, PCCA USA), tangerine oil flavor (\#30-2155, 1µL/dose, PCCA USA), steviol glycosides 95% (8.7 mg/dose, PCCA USA), citric acid USP anhydrous fine granular (12.5 mg/dose, Letco Medical LLC, Decatur, AL, USA), polysorbate 20 NF liquid (2 µL/dose, PCCA USA), and silica gel micronized powder (4 mg/dose, Letco). Gummies were administered to participants on day 0 and day 28 prior to influenza virus vaccination. Participants and healthcare providers were blinded throughout the vaccination and collection procedures.

### 2.1.3. Vaccine Components {#sec2dot1dot3-viruses-11-00907}

In season 2015--2016, the vaccine was FluMist^®^ (AstraZeneca, Cambridge, UK), whereas in seasons 2016--2017 and 2017--2018, the vaccines were Fluzone^®^ Quadrivalent (Sanofi Pasteur, Lyon, France) for children \< 3 years of age and Fluarix^®^ Quadrivalent (GlaxoSmithKline, Brentford, UK) for children of ≥ 3 years of age. These changes were due to revised recommendations by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC). Vaccine components changed in each influenza virus season. In 2015--2016, components were A/CA/7/09 H1N1, A/Switzerland/9715293/13 H3N2, B/Phuket/3073/13, and B/Brisbane/60/2008. In 2016--2017 components were A/CA/7/09 H1N1, A/Hong Kong/4801/14 H3N2, B/Phuket/3073/13, and B/Brisbane/60/2008, and in 2017--2018, components were A/Michigan/45/2015 H1N1, A/Hong Kong/4801/14 H3N2, B/Phuket/3073/13, and B/Brisbane/60/2008.

### 2.1.4. Blood Sample Collection {#sec2dot1dot4-viruses-11-00907}

Blood samples were collected at screening (≤10 days from day 0) and on days 0, 28, and 56. Participants who completed the day 28 visit were considered evaluable.

2.2. RBP, Retinol, and 25(OH)D Measurements {#sec2dot2-viruses-11-00907}
-------------------------------------------

Blood samples were preserved in the cold and dark according to standard guidelines. Levels of RBP were measured with an enzyme-linked immunosorbent assay (ELISA, R&D Systems \[Minneapolis, MN, USA\] human RBP4 Quantikine kits).

Retinol was measured by extraction from test samples under conditions of UV-blocked lighting with samples of SRM-968f human reference sera (NIST, <https://www-s.nist.gov/srmors/orderingSRMs.cfm>) used as controls. Samples were diluted with HPLC-grade water and then absolute ethanol and HPLC grade hexane. Tubes were vortexed, incubated for 30 min in the dark, and centrifuged. Hexane layers were removed. A second hexane extraction followed, which was combined with the first, and evaporated to dryness under nitrogen. Methanol:water:acetonitrile (10:20:70 by volume) was added followed by vortexing. Samples were transferred to UPLC vials, briefly centrifuged, and loaded into a Waters Acquity UPLC tray for injection onto a Waters Acquity BEH C-18 reverse phase column using methanol:water:acetonitrile (10:20:70) as the mobile phase. Standards of purified all-trans-retinol (0 to 0.8 pmol/10 µL) provided a standard curve (*R*^2^ \> 0.99).

25(OH)D was tested in the Pathology Department at St. Jude using the Roche Elecsys Vitamin D ELISA (Roche, Basel, Switzerland) that measures 25(OH)D metabolites of cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2). Vitamin D sufficiency was defined as ≥ 30 ng/mL 25(OH)D.

2.3. Hemagglutination Inhibition (HAI) Assay {#sec2dot3-viruses-11-00907}
--------------------------------------------

The HAI assay was conducted to evaluate antibody responses to each of the 4 components in the seasonal influenza virus vaccine. Briefly, antigen (\~4 agglutination doses representing each antigen) was added to wells of a 96-well plate containing serial dilutions of test sera (initiated with a 1:10 serum dilution followed by serial 1:2 dilutions, each tested in duplicate). After 30 min incubation at room temperature, 50 microliters of 0.5% *vol*/*vol* turkey red blood cells were added to each well and plates were incubated at room temperature for an additional 30 min. Titers were recorded as the highest dilution that inhibited hemagglutination. A few participants did not return for the day 56 visit. A score of 5 (1/2 the lowest dilution tested) was given if no HAI activity was detected. If two different values were observed for duplicate samples, the geometric mean value was used for graphing and calculation purposes.

2.4. Statistical Analyses {#sec2dot4-viruses-11-00907}
-------------------------

Results for each vaccine season were tested independently due to differences in vaccine composition each year. Spearman's rank correlation was applied to evaluate relationships involving ordinal variables. A generalized estimating equation (GEE) model was used to assess the effect of influenza vaccine plus A&D over time on HAI responses to each antigen among participants with different baseline vitamin levels. Specifically, the GEE model was constructed with log2-transformed HAI titers as the response, age, race, and a three-way interaction among time, baseline vitamin levels, and study groups as covariates, and the first order autoregressive (AR1) as the working correlation structure. Data analyses were performed using SAS 9.4 (SAS Institute, Inc, Cary, NC, USA) and GraphPad Prism software (San Diego, CA, USA).

3. Results {#sec3-viruses-11-00907}
==========

3.1. Participant Characteristics {#sec3dot1-viruses-11-00907}
--------------------------------

Age, sex, race, and baseline vitamin levels are shown for all three seasons and all participants in [Table 1](#viruses-11-00907-t001){ref-type="table"}. As shown, a different vaccine was administered to study participants each year, and FluMist^®^ was only used in season 2015--2016 due to revised recommendations by the CDC. As expected, baseline RBP and retinol levels were positively correlated (Spearman's correlation *r* = 0.7, *p* \< 0.0001), emphasizing that RBP can serve as a surrogate for retinol. An additional test of RBP was conducted on day 56 for placebo and A&D groups, but day 56 values were not significantly different from day 0 values in either group. Baseline HAI means and ranges are shown for each season ([Table 1](#viruses-11-00907-t001){ref-type="table"}). For HAI, data were not combined among years because vaccines and consequent immune responses differed. Full details for all participants and all years are provided in [Table A1](#viruses-11-00907-t0A1){ref-type="table"}, [Table A2](#viruses-11-00907-t0A2){ref-type="table"}, [Table A3](#viruses-11-00907-t0A3){ref-type="table"}, [Table A4](#viruses-11-00907-t0A4){ref-type="table"}, [Table A5](#viruses-11-00907-t0A5){ref-type="table"} and [Table A6](#viruses-11-00907-t0A6){ref-type="table"}.

[Table 2](#viruses-11-00907-t002){ref-type="table"} shows the frequencies of ≥ 4-fold increases in HAI titers by year and influenza virus antigen on days 28 and 56. As shown, the largest participant number was in season 2016--2017 (*n* = 44). Accordingly, results from this season were used for the primary analyses. For other seasons, descriptive analyses were performed due to limited available data.

For several vaccine components, baseline HAI titers were highly variable among study participants, a situation that may confound comparisons between participants and study groups. Fortuitously, for the B/Phuket/3073/13 vaccine in the 2016--2017 season, when enrollment was highest, baseline titers were all negative (highlighted in [Table 1](#viruses-11-00907-t001){ref-type="table"}).

3.2. Vitamin Supplements were Beneficial to Children with Insufficient Vitamin A and D Levels at Baseline {#sec3dot2-viruses-11-00907}
---------------------------------------------------------------------------------------------------------

To determine how baseline vitamin levels affected immune responses and benefits of vitamin supplementation, we characterized each participant from season 2016--2017 as being sufficient or insufficient/deficient for vitamins A or D at baseline, and accordingly assigned participants to one of four groups (e.g., the "Low A/Low D" group included individuals who were insufficient or deficient for both vitamins A and D). Cut-offs for sufficiency (termed "high") were ≥ 22,000 ng/mL for RBP and ≥ 30 ng/mL for 25(OH)D. The fold-change of HAI titers on days 28 and 56 compared to baseline were examined for each group ([Table 2](#viruses-11-00907-t002){ref-type="table"} and [Figure 1](#viruses-11-00907-f001){ref-type="fig"}.) The percentages of participants with a ≥ 4-fold rise in HAI activity on day 28 or day 56 compared to baseline are shown in [Table 2](#viruses-11-00907-t002){ref-type="table"}. Of particular interest, we found that children who were insufficient or deficient for both vitamins A and D (Low A/Low D) benefitted significantly from the A&D supplement ([Table 2](#viruses-11-00907-t002){ref-type="table"} and [Figure 1](#viruses-11-00907-f001){ref-type="fig"}.).

3.3. Vitamin Supplements were Ineffective or Inhibitory of Vaccine Responses among Children with Sufficient Levels of Vitamins A and/or D {#sec3dot3-viruses-11-00907}
-----------------------------------------------------------------------------------------------------------------------------------------

The benefit of A&D supplementation differed for children with sufficient levels of vitamins A and/or D at baseline compared to children who were insufficient or deficient. As shown in [Figure 1](#viruses-11-00907-f001){ref-type="fig"}, A&D benefits were not observed when children exhibited sufficient vitamin levels at baseline. In fact, for some responses, the A&D supplement conferred an inhibitory effect on HAI responses. Results help explain discrepancies in previous clinical studies by showing that the benefit of a vitamin supplement can be determined by the study participant's baseline vitamin levels.

3.4. Baseline RBP Correlates Positively, while Baseline 25(OH)D Correlates Negatively, with Immune Responses Toward Influenza Vaccine Components. {#sec3dot4-viruses-11-00907}
-------------------------------------------------------------------------------------------------------------------------------------------------

We next examined how baseline serum vitamin A and D levels correlated with HAI toward the four vaccine components in season 2016--2017 (A/CA/7/09 H1N1, A/Hong Kong/4801/14 H3N2, B/Phuket/3073/13, and B/Brisbane/60/2008). Correlations were evaluated between baseline RBP levels and HAI titers (including absolute HAI titers on day 28 and day 56, peak HAI titers, or changes in HAI titers between days 0 and 28 or days 0 and 56). As shown in [Figure 2](#viruses-11-00907-f002){ref-type="fig"}A and 2B, baseline RBP was positively correlated with HAI.

This result was more pronounced in the placebo group ([Figure 2](#viruses-11-00907-f002){ref-type="fig"}A) compared to the A&D group. Surprisingly, the same result was not observed for 25(OH)D. In this case, there were often negative correlations between 25(OH)D and the HAI immune response (i.e., a high 25(OH)D level at study entry associated with a low HAI response).

The negative correlation was more pronounced in the A&D group ([Figure 2](#viruses-11-00907-f002){ref-type="fig"}D) compared to the placebo group. Individual patient data for two of these correlations are shown in [Figure 2](#viruses-11-00907-f002){ref-type="fig"}E--F. As shown, the baseline RBP value was positively and significantly correlated with the day 28 HAI response toward B/Phuket/3073/13 in the placebo group (*r* = 0.6, *p* = 0.003, [Figure 2](#viruses-11-00907-f002){ref-type="fig"}E), and the baseline 25(OH)D value was negatively and significantly correlated with the day 28 HAI response toward B/Phuket/3073/13 in the A&D group (*r* = −0.5, *p* = 0.02, [Figure 2](#viruses-11-00907-f002){ref-type="fig"}F).

4. Discussion {#sec4-viruses-11-00907}
=============

Our clinical study was designed to investigate how baseline vitamins A and D influence the immune response to influenza virus vaccines. We found that baseline vitamin A levels (scored by RBP) correlated positively with immune responses, particularly toward the B/Phuket/3073/13 vaccine component in the placebo group in season 2016--2017. However, negative correlations were observed between baseline 25(OH)D and the immune response, particularly in the group that received vitamin supplementation. The vitamin A&D supplement significantly improved immune responses toward the B/Phuket/3073/13 vaccine in season 2016--2017 but only when baseline vitamin A and D levels were insufficient at baseline. The supplement had no significant effect or weakened the HAI response when baseline RBP and 25(OH)D levels were sufficient.

Our results were somewhat surprising given that vitamins are often viewed as positively associated with immune responses. Our observation that 25(OH)D correlated negatively with vaccine-induced HAI appeared contrary to the report by Chadha et al. who observed a positive influence of vitamin D on the immune response to influenza virus in cancer patients \[[@B15-viruses-11-00907]\]. Of note, not all researchers have agreed that vitamins are beneficial. Some authors have argued that "too much" vitamin can have a negative influence on the immune response to vaccines \[[@B5-viruses-11-00907],[@B34-viruses-11-00907],[@B40-viruses-11-00907],[@B44-viruses-11-00907],[@B45-viruses-11-00907]\]. Lee et al. (described above), Principi et al. \[[@B41-viruses-11-00907]\], and Kriesel et al. \[[@B64-viruses-11-00907]\] each failed to identify an influence of vitamin D on influenza virus-specific responses. In the latter two studies vitamin D supplements were administered to influenza virus vaccine participants but supplements did not improve vaccine-induced immune responses. A study by Lin et al. \[[@B45-viruses-11-00907]\] showed a negative association between vitamin D levels and responses to type B influenza viruses. Our data help to explain the differing results and interpretations of previous literature by showing that baseline vitamin A and baseline vitamin D levels each affect outcome; we found that the benefit of a vitamin A&D supplement was only evident when children were insufficient or deficient in both RBP and 25(OH)D at study entry.

To explain why 25(OH)D could have a negative influence on immune responses to influenza virus vaccines, we consider the vitamin's capacity to clear pathogens. Vitamin D upregulates cathelicidin, an anti-microbial peptide \[[@B65-viruses-11-00907],[@B66-viruses-11-00907]\] that can denature and clear both bacteria and viruses, including influenza virus. Perhaps children who were 25(OH)D replete (due to diet and/or the A&D supplement) rapidly cleared vaccine antigens, thus removing the trigger for an antibody response. The influenza virus vaccine is not adjuvanted and may have been particularly vulnerable to cathelicidin-induced damage. A suggestion of rapid vaccine clearance in the presence of high vitamin levels was similarly proposed by Semba et al. when their vitamin A supplementation of 6 month old infants was found to inhibit antibody responses to the measles vaccine \[[@B44-viruses-11-00907]\]. Another explanation for vitamin D inhibition of HAI may relate to the vitamin's capacity to alter innate and adaptive immune cell trafficking in vivo, and to inhibit B cell proliferation and survival in vitro \[[@B1-viruses-11-00907],[@B67-viruses-11-00907]\]. One final consideration concerns the contrasting influences of vitamins A and D; vitamin D has been positively correlated with serum IgM and IgG3, whereas vitamin A has been positively correlated with other isotypes that might better support HAI \[[@B11-viruses-11-00907],[@B68-viruses-11-00907],[@B69-viruses-11-00907],[@B70-viruses-11-00907]\]. If vitamin D and its receptor blocked the binding of RAR to DNA response elements, vitamin D may have inhibited positive influences of vitamin A \[[@B27-viruses-11-00907]\].

Our study had limitations because more than one factor could have influenced HAI responses and data interpretation. The phenotypes and functions of individual T cell populations, B cell populations and innate immune cells were not analyzed in our study. T cell and antigen presenting cell (APC) populations are particularly important as drivers of B cell activation, proliferation, and antibody expression. Each can be influenced by vitamin levels. In vitamin A deficient mice, for example, CD103 is significantly upregulated on dendritic cell (DC) and T cell membranes \[[@B1-viruses-11-00907],[@B12-viruses-11-00907]\]. CD103 is the αE component of the αEβ7 integrin, which binds the epithelial cell marker E-cadherin. Changes in homing receptor expression affect DC and T cell trafficking/residence and thereby alter antigen presentation and the "help" T cells provide to virus-specific B cells \[[@B1-viruses-11-00907],[@B12-viruses-11-00907],[@B71-viruses-11-00907]\]. The plethora of indirect and direct influences of nuclear hormones on the B cell response (including nuclear hormone receptor binding to enhancers and switch regions of the immunoglobulin heavy chain locus \[[@B28-viruses-11-00907],[@B29-viruses-11-00907],[@B58-viruses-11-00907]\]) may explain some of the complex outcomes of clinical studies. Our primary data were from season 2016--2017 with the highest enrollment; smaller datasets from other seasons were sufficient only for observation and not for confirmatory analyses. We note differences between HAI responses to the four components in each vaccine. For example, among individuals with low baseline RBP and low baseline 25(OH)D levels in the 2016--2017 season, the most significant improvements in vaccine-induced responses in the A&D group compared to the placebo group were toward the B/Phuket/3073/13 vaccine component. In this case, our analyses of vaccine-induced immune responses benefitted from the harmonious and negative HAI responses toward B/Phuket/3073/13 among study participants at baseline; in contrast, study participants exhibited variable and confounding baseline responses toward the other three vaccine components ([Table 1](#viruses-11-00907-t001){ref-type="table"}). Another limitation of our study was that subclinical or clinical exposures to cross-reactive viral antigens by study participants before or during vaccination may have contributed to outcomes \[[@B72-viruses-11-00907],[@B73-viruses-11-00907]\]. One individual in the placebo group of the 2016--2017 season (ID \#58, [Table A2](#viruses-11-00907-t0A2){ref-type="table"}) had a confirmed influenza virus infection and one individual in the placebo group of season 2017--2018 (ID \#66, [Table A3](#viruses-11-00907-t0A3){ref-type="table"}) reported an exposure to family members with confirmed influenza virus infections.

Despite the limitations noted above, our data provide an explanation for conflicting results in previous vitamin supplementation studies. As in our study, responses to vaccine antigens and vitamin supplements in other studies were likely dependent on baseline vitamin levels \[[@B40-viruses-11-00907]\]. Unfortunately, in past studies, baseline levels of vitamin A, vitamin D, or both, were often untested and/or unreported. Our study provides guidance for the suitability of adding vitamin A and D measurements to future clinical vaccine protocols to improve data interpretation and thereby improve vaccine efficacy and infection control in children. Finally, our results support a recommendation to use vitamin A and D supplements with influenza vaccines in areas where children are frequently vitamin deficient or insufficient but not in areas where children are frequently replete for vitamins A and D.
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viruses-11-00907-t0A1_Table A1

###### 

Patient Characteristics 2015--2016.

  ID   Sex      Age   Race    Date        RBP (ng/mL)   Retinol (µg/dL)   Vitamin D (ng/mL)   Assn.
  ---- -------- ----- ------- ----------- ------------- ----------------- ------------------- -------
  1    Female   3     Black   2/11/2016   27,123        26.58             41.66               A
  2    Male     7     Black   2/15/2016   25,607        31.36             21.14               B
  3    Female   2     Black   2/15/2016   25,056        23.06             23.99               A
  4    Female   8     Black   2/16/2016   20,523        30.98             14.39               B
  5    Male     4     Black   2/24/2016   12,970        12.15             17.76               A
  6    Female   6     Black   2/24/2016   16,248        22.10             24.3                B
  7    Female   8     Black   2/24/2016   24,314        37.77             17.16               B
  8    Male     4     Black   2/29/2016   21,660        33.59             21.52               B
  9    Female   5     Black   2/29/2016   19,773        21.49             22.29               A

Assignments (Assn.) were A = Placebo, B = Vit A&D.

viruses-11-00907-t0A2_Table A2

###### 

Patient Characteristics 2016--2017.

  ID   Sex      Age   Race    Date         RBP (ng/mL)   Retinol (µg/dL)   Vitamin D (ng/mL)   Assn.
  ---- -------- ----- ------- ------------ ------------- ----------------- ------------------- -------
  13   Female   8     White   9/26/2016    26,208        31.48             40.32               B
  14   Male     7     Black   10/6/2016    19,967        40.69             25.67               A
  15   Male     2     Black   10/6/2016    18,628        25.42             40.83               B
  16   Male     5     Black   10/14/2016   29,270        40.74             20.46               B
  17   Male     7     Black   10/14/2016   22,039        42.72             17.83               A
  19   Male     3     Black   10/18/2016   14,717        17.48             17.52               A
  20   Female   5     Black   10/21/2016   28,408        33.55             19.94               B
  21   Female   2     Black   10/21/2016   22,691        33.41             24.42               A
  22   Male     2     White   10/31/2016   22,773        32.63             32.1                A
  23   Male     4     Black   11/1/2016    25,284        38.87             38.07               B
  24   Female   4     Black   11/1/2016    21,511        34.75             32.94               A
  25   Female   8     Black   11/4/2016    28,509        41.73             26.36               A
  26   Female   8     Black   11/4/2016    27,407        37.28             31.06               A
  27   Male     3     Black   11/2/2016    21,077        34.72             43.38               B
  28   Female   8     White   11/10/2016   31,602        45.56             33.12               B
  29   Female   5     White   11/10/2016   28,462        36.71             35.72               B
  30   Female   8     White   11/18/2016   16,262        37.40             35.09               B
  31   Female   6     White   11/18/2016   18,033        34.69             33.81               B
  32   Female   7     White   11/18/2016   16,513        27.47             30.6                B
  33   Male     2     White   11/18/2016   20,789        32.81             33.9                A
  34   Female   3     White   11/22/2016   19,763        30.25             47.91               A
  35   Male     7     Black   11/29/2016   21,604        37.01             23.56               B
  36   Female   4     Black   12/5/2016    22,322        33.55             18.34               A
  38   Female   2     Black   12/13/2016   9,563         18.06             14.29               B
  39   Male     3     Black   12/13/2016   18,423        37.10             38.66               A
  40   Female   5     Black   12/13/2016   20,554        43.13             41.98               A
  41   Female   2     Black   12/29/2016   15,620        29.52             18.44               A
  42   Female   8     Black   12/29/2016   23,453        31.06             21.21               A
  45   Female   3     Black   1/5/2017     28,088        54.87             27.05               B
  46   Female   4     Black   1/5/2017     18,416        30.00             23.72               A
  47   Female   3     Black   1/13/2017    23,044        34.92             30.79               B
  48   Female   8     Black   1/19/2017    27,113        39.94             19.17               B
  49   Female   2     Black   1/20/2017    18,946        26.15             20.18               B
  50   Male     6     Black   1/20/2017    21,196        34.16             16.4                B
  51   Male     4     Black   1/24/2017    23,402        36.74             20.44               A
  53   Female   5     Black   1/26/2017    24,518        35.92             21.74               A
  54   Female   6     Black   1/26/2017    22,327        32.28             27.14               A
  55   Female   6     Black   1/27/2017    14,551        19.57             23.7                B
  57   Male     7     White   2/9/2017     32,563        55.81             31.88               A
  58   Female   8     White   2/20/2017    19,934        29.56             31.52               A
  60   Female   6     Black   3/3/2017     21,408        33.01             15.95               B
  61   Female   4     White   3/7/2017     22,007        31.90             35.13               A
  62   Male     5     White   3/7/2017     24,650        30.95             32.71               B
  64   Male     2     Black   3/31/2017    28,602        36.90             42.95               B

Assignments (Assn.) were A = Placebo, B = Vit A&D.

viruses-11-00907-t0A3_Table A3

###### 

Patient Characteristics 2017--2018.

  ID   Sex      Age   Race    Date         RBP (ng/mL)   Retinol (µg/dL)   Vitamin D (ng/mL)   Assn.
  ---- -------- ----- ------- ------------ ------------- ----------------- ------------------- -------
  66   Male     3     White   9/18/2017    26,710        38.11             33.6                B
  67   Female   8     Black   9/20/2017    30,555        43.65             31.28               B
  68   Female   8     White   10/13/2017   25,711        37.70             43.25               A
  70   Male     2     White   10/20/2017   22,600        34.30             39.52               B
  71   Male     8     White   10/20/2017   21,556        43.41             30.74               A
  72   Male     2     White   10/20/2017   30,109        36.38             34.36               A
  73   Male     2     White   10/20/2017   29,917        41.63             53.05               A
  74   Female   2     White   10/30/2017   17,973        26.53             34.74               B
  75   Female   2     Black   11/2/2017    22,499        33.34             17.04               B
  78   Female   2     Black   11/15/2017   20,178        28.53             56.76               A
  79   Male     6     Black   11/16/2017   20,113        34.33             26.05               A
  80   Female   8     Black   11/17/2017   16,137        25.51             13.68               B
  81   Female   2     Black   11/17/2017   20,112        29.38             23.76               A
  83   Male     2     Black   12/5/2017    35,501        47.44             31.49               B
  84   Female   8     Black   12/8/2017    15,692        21.53             23.13               A
  85   Male     3     Black   12/12/2017   18,809        26.27             28.4                B
  86   Male     8     Black   12/12/2017   31,920        44.38             18.75               A
  87   Male     8     Black   1/9/2018     37,539        51.88             35.06               B
  88   Male     7     Black   1/9/2018     23,074        30.49             37.53               A
  89   Female   7     White   2/19/2018    19,055        27.30             25.16               B
  90   Female   7     Black   2/20/2018    26,643        38.93             26.8                A
  92   Female   8     Black   3/13/2018    30,636        36.42             10.06               B
  94   Male     2     Black   3/28/2018    13,348        18.49             20.32               B
  95   Female   4     Black   3/26/2018    26,157        29.94             12.97               A
  96   Male     2     Black   4/5/2018     20,866        28.02             53.52               A
  97   Male     2     White   4/23/2018    25,638        36.52             39.14               A

Assignments (Assn.) were A = Placebo, B = Vit A&D.

viruses-11-00907-t0A4_Table A4

###### 

HAI results 2015--2016.

  A.   Day 0   Day 28    Day 56                                                              
  ---- ------- --------- -------- ------ ------ --------- ------ ------ ------ ------ ------ ------
  1    \<10    \<10      \<10     \<10   \<10   320/640   \<10   \<10   \<10   160    \<10   \<10
  2    \<10    640       40       \<10   \<10   320       160    \<10   \<10   320    80     \<10
  3    \<10    \<10      \<10     \<10   \<10   160       \<10   \<10   \<10   1280   \<10   \<10
  4    160     \<10      \<10     \<10   160    \<10      \<10   \<10   320    \<10   \<10   \<10
  5    20      160       \<10     \<10   \<10   320       \<10   \<10   \<10   320    \<10   \<10
  6    \<10    \<10      \<10     \<10   \<10   1280      \<10   \<10   \<10   1280   \<10   \<10
  7    40      160/80    \<10     \<10   \<10   \<10      \<10   \<10   \<10   80     \<10   \<10
  8    \<10    \<10      \<10     \<10   \<10   640       \<10   \<10   \<10   320    \<10   \<10
  9    40      320/640   \<10     \<10   40     320       \<10   \<10   \<10   640    \<10   \<10

viruses-11-00907-t0A5_Table A5

###### 

HAI results Season 2016--2017.

  ID   Day 0     Day 28   Day 56                                                                          
  ---- --------- -------- -------- ------ ------ ----------- ------ ----------- ------ ----------- ------ --------
  13   \<10      640      \<10     \<10   640    20480       10     640         640    20480       \<10   160
  14   40        \<10     \<10     \<10   320    640         \<10   \<10        640    640         \<10   \<10
  15   \<10      \<10     \<10     \<10   \<10   \<10        \<10   \<10        80     40          \<10   \<10
  16   320/640   320      \<10     \<10   640    5120        80     80          1280   2560        80     \<10
  17   320       40       \<10     \<10   640    640         80     80          1280   320         40     20
  19   \<10      320      \<10     \<10   \<10   2560/5120   \<10   320         N/S    N/S         N/S    N/S
  20   40        80       \<10     \<10   640    5120        40     80          640    5120        40     40
  21   10        \<10     \<10     \<10   160    1280        40     40          320    1280        40     40
  22   10        \<10     \<10     \<10   1280   1280/2560   80     320         2560   2560        160    320
  23   20        80       \<10     \<10   320    320         40     320         160    320         40     80/160
  24   \<10      \<10     \<10     \<10   1280   320         40     320         640    160         10     80/160
  25   10        \<10     \<10     \<10   160    160         80     160         320    160         160    160
  26   \<10      320      \<10     \<10   320    10240       40     20          320    5120        \<10   \<10
  27   320/640   \<10     \<10     \<10   640    160         \<10   20          N/S    N/S         N/S    N/S
  28   \<10      160      \<10     \<10   640    320         \<10   \<10        160    320         \<10   \<10
  29   \<10      \<10     \<10     \<10   1280   1280        \<10   \<10        640    1280        \<10   \<10
  30   \<10      2560     \<10     \<10   \<10   5120        80     \<10        \<10   2560        \<10   \<10
  31   \<10      650      \<10     \<10   \<10   640         \<10   \<10        \<10   2560/1280   \<10   \<10
  32   \<10      \<10     \<10     \<10   320    640         \<10   \<10        640    640         \<10   \<10
  33   \<10      \<10     \<10     \<10   320    640/1280    20     40          640    640         \<10   \<10
  34   \<10      \<10     \<10     \<10   \<10   \<10        \<10   \<10        160    \<10        \<10   \<10
  35   160       160      \<10     \<10   640    2560        80     \<10        1280   2560        \<10   \<10
  36   \<10      320      \<10     \<10   \<10   2560        \<10   80          160    2560/1280   \<10   \<10
  38   \<10      \<10     \<10     \<10   640    640/1280    80     80          1280   1280        160    \<10
  39   160       160      \<10     \<10   640    2560        80     160         640    1280/2560   80     160
  40   40        160      \<10     \<10   320    160         160    40          640    160         80     \<10
  41   320       \<10     \<10     \<10   2560   \<10        \<10   \<10        2560   160         \<10   \<10
  42   \<10      160      \<10     \<10   2560   1280        320    640         2560   640/1280    320    320
  45   640       2560     \<10     160    640    160/2560    \<10   160         1280   1280/2560   80     160
  46   640       1280     \<10     \<10   1280   2560        \<10   320         640    2560        \<10   160
  47   \<10      640      \<10     \<10   \<10   10240       \<10   \<10        80     10240       \<10   \<10
  48   160       320      \<10     \<10   1280   2560        160    1280        1280   5120        80     640
  49   320       \<10     \<10     \<10   640    640         80     \<10        320    640         \<10   \<10
  50   320       1280     \<10     \<10   1280   2560        80     80/160      640    1280        \<10   80
  51   320       160      \<10     \<10   640    2560        \<10   80          1280   2560        80     80/160
  53   80        \<10     \<10     80     1280   160         160    \<10        N/S    N/S         N/S    N/S
  54   320       80       \<10     \<10   1280   1280        160    320         2560   1280        80     160
  55   \<10      \<10     \<10     \<10   320    1280        \<10   \<10        640    2560        \<10   \<10
  57   \<10      160      \<10     \<10   1280   1280/2560   320    80          640    1280        160    40
  58   \<10      160      \<10     \<10   320    320         \<10   320/640     320    640         80     320
  60   320       640      \<10     \<10   2560   5120        \<10   2560/5120   2560   2560        \<10   2560
  61   \<10      1280     \<10     \<10   160    1280        \<10   \<10        160    1280        \<10   \<10
  62   \<10      320      \<10     \<10   1280   320         \<10   20          640    160         \<10   \<10
  64   \<10      \<10     \<10     \<10   160    80          \<10   \<10        160    160         \<10   \<10

N/S = no sample.

viruses-11-00907-t0A6_Table A6

###### 

HAI results 2017--2018.

  ID   Day 0     Day 28   Day 56                                                                             
  ---- --------- -------- -------- ------ ------ ------- -------- --------- ----------- ----------- -------- ---------
  66   640       160      \<10     \<10   2560   160     \<10     \<10      5120        320         \<10     \<10
  67   \<10      320      \<10     160    2560   1280    160      \<10      2560        2560        \<10     320/640
  68   \<10      \<10     \<10     \<10   40     2560    \<10     320       2560        1280        \<10     640
  70   \<10      80       \<10     \<10   1280   640     \<10     \<10      40          640         \<10     \<10
  71   160       320      \<10     \<10   160    640     \<10     80        1280        640         \<10     \<10
  72   \<10      \<10     \<10     \<10   160    10      \<10     \<10      320         \<10        \<10     \<10
  73   \<10      \<10     \<10     \<10   10     10      \<10     \<10      80          40          \<10     \<10
  74   \<10      \<10     \<10     \<10   320    80      \<10     \<10      640         80          80       \<10
  75   \<10      \<10     \<10     \<10   160    80      \<10     320       320         160         \<10     320
  78   \<10      320      \<10     \<10   160    5120    \<10     \<10      1280        5120        \<10     \<10
  79   320       320      \<10     \<10   2560   5120    80       \<10      2560        2560        80       \<10
  80   1280      640      \<10     160    2560   1280    \<10     160/320   640         1280        80       160/320
  81   320       \<10     \<10     \<10   640    320     \<10     \<10      1280        640         80/160   80
  83   320       160      10       40     640    10240   160      320       1280        2560        80/160   320
  84   1280      1280     80       160    5120   5120    80/160   80/160    2560        1280        160      320
  85   320       80       \<10     \<10   1280   5120    40       80        640         640         \<10     \<10
  86   1280      1280     \<10     \<10   5120   5120    \<10     \<10      10240       2560/5120   \<10     80
  87   160       1280     \<10     \<10   1280   5120    \<10     \<10      640/1280    2560        80       \<10
  88   160       1280     160      80     640    640     320      160       640         1280        160      160
  89   5120      \<10     \<10     \<10   2560   320     \<10     \<10      2560/5120   160         \<10     \<10
  90   80        \<10     \<10     \<10   5120   320     \<10     160       5120        320         160      160
  92   160       640      \<10     \<10   5120   2560    \<10     160       5120        2560        40/80    80
  94   320       \<10     \<10     \<10   640    160     \<10     \<10      N/S         N/S         N/S      N/S
  95   1280      320      \<10     \<10   640    640     \<10     \<10      640         320         80       80
  96   320/640   320      \<10     \<10   5120   10240   \<10     \<10      2560        5120        \<10     \<10
  97   \<10      \<10     80       \<10   160    160     80       \<10      160         \<10        \<10     \<10

N/S = no sample.

![Estimated fold change in hemagglutination inhibition (HAI) responses compared between placebo (black) and vitamin A and D supplement (A&D, red) study groups at different time points of the study in season 2016--2017. Participants were placed into one of four groups based on vitamin levels. Cut-offs for sufficiency (termed "high") were ≥ 22,000 ng/mL for retinol-binding protein (RBP) and ≥ 30 ng/mL for 25(OH)D. Groups were "Low A/Low D", *n* = 10; "High A/Low D", *n* = 12; "Low A/High D," *n* = 11; "High A/High D," *n* = 11 (see [Table 2](#viruses-11-00907-t002){ref-type="table"}). For each of the four viruses, the GEE model was constructed with log2-transformed HAI titers as the response, age, race, and a three-way interaction among time, incoming vitamin levels, and study groups as covariates, and the first order autoregressive (AR1) as the working correlation structure. Estimated mean fold changes are plotted with 90% confidence intervals. *p*-values were obtained from post hoc comparisons from GEE models (\* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001).](viruses-11-00907-g001){#viruses-11-00907-f001}

![Relationships between baseline vitamin levels and HAI responses in season 2016--2017. Spearman correlation coefficients are plotted for comparisons between baseline vitamin levels and HAI titers among participants enrolled during the 2016--2017 season. R values are plotted on the Y axis in A--D. Positive correlations are indicated in green and negative correlations are indicated in red. The top row shows RBP correlations with HAI titers in placebo (**A**) and A&D (**B**) groups. Specifically, correlations are shown between baseline RBP and day 0 HAI, baseline RBP and day 28 HAI, baseline RBP and day 56 HAI, baseline RBP and peak HAI, baseline RBP and changes in HAI between days 0 and 28, and baseline RBP and changes in HAI between days 0 and 56. \* *p* \< 0.05; \*\* *p* \< 0.01; \*\*\* *p* \< 0.001. The middle row substitutes 25(OH)D for RBP in placebo (**C**) and A&D (**D**) groups. In the bottom row, detailed correlative data are shown for RBP versus B/Phuket/3073/13 HAI titers on day 28 in the placebo group (*n* = 22, some values overlap) (**E**), and 25(OH)D versus B/Phuket/3073/13 HAI titers on day 28 in the A&D group (*n* = 22, some values overlap) (**F**).](viruses-11-00907-g002){#viruses-11-00907-f002}

viruses-11-00907-t001_Table 1

###### 

Baseline patient characteristics.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                All Seasons\                   2015--2016 Season\   2016--2017 Season\   2017--2018 Season\                                                                  
                                                 FluMist, Fluzone, or Fluarix   FluMist              Fluzone or Fluarix   Fluzone or Fluarix                                                                  
  ---------------------------------------------- ------------------------------ -------------------- -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
  Age groups, *n* (%)                                                                                                                                                                                         

  2--4 years                                     22 (55 %)                      16 (41%)             3 (75%)              1 (20%)              12 (54.5%)           8 (36%)              7 (50%)              7 (58%)

  5--8 years                                     18 (45 %)                      23 (59%)             1 (25%)              4 (80%)              10 (45.5%)           14 (64%)             7 (50%)              5 (42%)

  Sex, *n* (%)                                                                                                                                                                                                

  Female                                         23 (57.5%)                     23 (59%)             3 (75%)              3 (60%)              14 (64%)             14 (64%)             6 (43%)              6 (50%)

  Male                                           17 (42.5%)                     16 (41%)             1 (25%)              2 (40%)              8 (36%)              8 (36%)              8 (57%)              6 (50%)

  Race, *n* (%)                                                                                                                                                                                               

  White                                          11 (27.5%)                     11 (28%)             0 (0%)               0 (0%)               6 (27%)              7 (32%)              5 (36%)              4 (33%)

  Black                                          29 (72.5%)                     28 (72%)             4 (100%)             5 (100%)             16 (73%)             15 (68%)             9 (64%)              8 (67%)

  RBP, *n* (%)                                                                                                                                                                                                

  \<22,000 ng/mL                                 18 (45%)                       19 (49%)             2 (50%)              3 (60%)              10 (45.5%)           11 (50%)             6 (43%)              5 (42%)

  ≥22,000 ng/mL                                  22 (55%)                       20 (51%)             2 (50%)              2 (40%)              12 (54.5%)           11 (50%)             8 (57%)              7 (58%)

  Vitamin D, *n* (%)                                                                                                                                                                                          

  \<30 ng/mL                                     21 (52.5%)                     21 (54%)             3 (75%)              5 (100%)             12 (54.5%)           10 (45.5%)           6 (43%)              6 (50%)

  ≥30 ng/mL                                      19 (47.5%)                     18 (46%)             1 (25%)              0 (0%)               10 (45.5%)           12 (54.5%)           8 (57%)              6 (50%)

  Retinol, *n* (%)                                                                                                                                                                                            

  \<20 µg/dL                                     2 (5%)                         3 (7.7%)             1 (25%)              0 (0%)               1 (4.6%)             2 (9%)               0 (0%)               1 (8.3%)

  20--30 µg/dL                                   11 (27.5%)                     8 (20.5%)            3 (75%)              1 (20%)              3 (13.6%)            3 (14%)              5 (36%)              4 (33.3%)

  \>30 µg/dL                                     27 (67.5%)                     28 (71.8%)           0 (0%)               4 (80%)              18 (81.8%)           17 (77%)             9 (64%)              7 (58.3%)

  Baseline HAI titer (log2), median (min, max)                                                                                                                                                                

  B/Phuket                                       \-\--^\#^                      \-\--                2.32 (2.32, 2.32)    2.32 (2.32, 5.32)    2.32 (2.32, 2.32)    2.32 (2.32, 2.32)    2.32 (2.32, 7.32)    2.32 (2.32, 3.32)

  B/Brisbane                                     \-\--                          \-\--                2.32 (2.32, 2.32)    2.32 (2.32, 2.32)    2.32 (2.32, 6.32)    2.32 (2.32, 7.32)    2.32 (2.32, 7.32)    2.32 (2.32, 7.32)

  H1N1 ^\*^                                      \-\--                          \-\--                3.32 (2.32, 5.32)    2.32 (2.32, 7.32)    3.32 (2.32, 9.32)    2.32 (2.32, 9.32)    7.32 (2.32, 10.32)   7.82 (2.32, 12.32)

  H3N2 ^\*^                                      \-\--                          \-\--                4.82 (2.32, 8.82)    2.32 (2.32, 9.32)    6.82 (2.32, 10.32)   7.32 (2.32, 11.32)   8.32 (2.32, 10.32)   6.82 (2.32, 10.32)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The numbers and characteristics of study participants in all seasons and in each of the three seasons are shown, with levels for RBP, vitamin D (25(OH)D), and retinol. HAI titers are shown for each season. ^\#^HAI titers were not combined among seasons because the vaccine changed each year. In 2015--2016, vaccine components were A/CA/7/09 H1N1, A/Switzerland/9715293/13 H3N2, B/Phuket/3073/13, and B/Brisbane/60/2008. In 2016--2017 components were A/CA/7/09 H1N1, A/Hong Kong/4801/14 H3N2, B/Phuket/3073/13, and B/Brisbane/60/2008, and in 2017--2018 components were A/Michigan/45/2015 H1N1, A/Hong Kong/4801/14 H3N2, B/Phuket/3073/13, and B/Brisbane/60/2008. When an HAI value was below detection, the sample was given a value of 5 (log2 2.32). Tests were conducted in duplicate and geometric means were determined. The negative baseline responses toward B/Phuket/3073/13 among all participants in season 2016--2017 are highlighted. For conversion, 30 µg/dL retinol = 1.05 µmol/L; 20 ng/mL 25(OH)D = 50 nmol/L. ^\*^ H1N1 and H3N2 components differed between seasons.

viruses-11-00907-t002_Table 2

###### 

HAI response (≥4 fold change) after the first or second vaccine doses.

  ----------------------------------------------------------------------------------------------- ------------- ------------ ------------- ------------- ------------- ------------- ------------- -------------
  **HAI Response** **(≥4 Fold Change) after the 1st Dose (Day 28 HAI Titer Compared to Day 0)**                                                                                                    
  2015--2016 (*n* = 9)                                                                            0/4 (0%)      1/5 (20%)    0/4 (0%)      0/5 (0%)      0/4 (0%)      0/5 (0%)      2/4 (50%)     2/5 (40%)
  2016--2017 (*n* = 44)                                                                           13/22 (59%)   9/22 (41%)   17/22 (77%)   10/22 (45%)   16/22 (73%)   14/22 (64%)   16/22 (73%)   15/22 (68%)
  2017--2018 (*n* = 26)                                                                           1/14 (7%)     3/12 (25%)   3/14 (21%)    4/12 (33%)    10/14 (71%)   8/12 (67%)    9/14 (64%)    10/12 (83%)
  2016--2017 (*n* = 44)                                                                                                                                                                            
  Low A and Low D (*n* = 10)                                                                      0/4 (0%)      4/6 (67%)    2/4 (50%)     3/6 (50%)     2/4 (50%)     5/6 (83%)     2/4 (50%)     5/6 (83%)
  High A and Low D (*n* = 12)                                                                     6/8 (75%)     3/4 (75%)    7/8 (88%)     3/4 (75%)     5/8 (63%)     2/4 (50%)     8/8 (100%)    3/4 (75%)
  Low A and High D (*n* = 11)                                                                     4/6 (67%)     1/5 (20%)    5/6 (83%)     1/5 (20%)     5/6 (83%)     1/5 (20%)     3/6 (50%)     2/5 (40%)
  High A and High D (*n* = 11)                                                                    3/4 (75%)     1/7 (14%)    3/4 (75%)     3/7 (43%)     4/4 (100%)    6/7 (86%)     3/4 (75%)     5/7 (71%)
  **HAI Response (≥4 Fold Change) after the 2nd Dose (Day 56 HAI Titer Compared to Day 0)**                                                                                                        
  2015--2016 (*n* = 9)                                                                            0/4 (0%)      0/5 (0%)     0/4 (0%)      0/5 (0%)      0/4 (0%)      0/5 (0%)      2/4 (50%)     2/5 (40%)
  2016--2017 (*n* = 41)                                                                           11/20 (55%)   6/21 (29%)   12/20 (60%)   6/21 (29%)    19/20 (95%)   15/21 (71%)   16/20 (80%)   15/21 (71%)
  2017--2018 (*n* = 25)                                                                           4/14 (29%)    5/11 (45%)   5/14 (36%)    3/11 (27%)    12/14 (86%)   8/11 (73%)    7/14 (50%)    8/11 (73%)
  2016--2017 (*n* = 41)                                                                                                                                                                            
  Low A and Low D (*n* = 9)                                                                       0/3 (0%)      1/6 (17%)    1/3 (33%)     2/6 (33%)     2/3 (67%)     4/6 (67%)     2/3 (67%)     5/6 (83%)
  High A and Low D (*n* = 11)                                                                     6/7 (86%)     4/4 (100%)   6/7 (86%)     2/4 (50%)     7/7 (100%)    2/4 (50%)     7/7 (100%)    3/4 (75%)
  Low A and High D (*n* = 10)                                                                     3/6 (50%)     0/4 (0%)     3/6 (50%)     0/4 (0%)      6/6 (100%)    2/4 (50%)     4/6 (67%)     2/4 (50%)
  High A and High D (*n* = 11)                                                                    2/4 (50%)     1/7 (14%)    2/4 (50%)     2/7 (29%)     4/4 (100%)    7/7 (100%)    3/4 (75%)     5/7 (71%)
  ----------------------------------------------------------------------------------------------- ------------- ------------ ------------- ------------- ------------- ------------- ------------- -------------

The vitamin group with the greater frequency of responses toward each vaccine component in season 2016--2017 is highlighted. ^\*^H1N1 and H3N2 changed between years. A few participants did not return for the day 56 visit.
